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-The Biological Basis of the Oocyte Assisted 
Reprogramming (OAR) Hypothesis: 
Is It an Ethical Procedure for Making 
Embryonic Stem Cells? 
by 
William Burke, M.D., Ph.D., Patrick Pullicino, M.D., Ph.D., 
and The Rev. Edward J. Richard, MS, DThM, JD 
Dr. Burke is Professor of Neurology, Associate Professor in Medicine, and 
Associate Professor in Anatomy and Neurobiology at Saint Louis 
University Health Sciences Center. Dr. Pullicino is Professor of Clinical 
Neurosciences, Kent Institute of Medicine and Health Sciences, 
Canterbury, Kent, England. The Rev. Richard is Vice-Rector, Dean of 
Students and Associate Professor of Moral Theology, Kenrick Glennon 
Seminary, St. Louis, MO. 
In response to the continuing controversy over embryonic stem cell (ESC) 
research, 35 ethicists and scientists have expressed their suppOtt for a new 
research proposal which they believe may yield pluripotent stem cells 
while circumventing the "creation" or destruction of human embryos. 
Their joint statement, issued June 20,2005, is accessible on the Ethics and 
Public Policy Center web site: 
www.eppc.org/publications/pubID.2374/pub detail.asp 
The joint statement was also published in Origins, the official pUblication 
of the US Bishops' Conference (7 July 2005, p.126ff). 
This research proposal is called Oocyte Assisted Reprogramming 
(OAR), and the initial research would involve experiments with mice! but 
would proceed to hWl1an experiments if results look promising. OAR is a 
form of Altered Nuclear Transfer (ANT). Both OAR and ANT use a 
modified version of a procedure called somatic cell nuclear transfer 
(SCNT), previously named therapeutic cloning. 
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Embryo Development 
In normal development a zygote cell divides into two cells called 
blastomeres. The cells remain totipotent for 2-3 days until the 4-8 cell stage 
when the embryo genome becomes activated.2,3,4 Up until this time, mRNA 
and proteins, deposited in the unfertilized egg by the mother's genome, 
control cell cleavage. 5 These cells continue to divide such that at the 8 cell 
stage the developing human being is called a morula. At about 60-150 
cells, a stage called the blastocyst is reached.3,6 The early developmental 
stages of the embryo appear devoted to cell cleavage and patteming which 
determines, through a gradient distribution of oocyte mRNA during 
cleavage,5 which part of the embryo will come to constitute its anterior-
posterior and dorsal-ventral axes and right and left sides. The genome 
remains inactive and totipotent during these early stages of 
development. 2,3,4 The blastocyst contains two types of cells6 : 
1) Embryonic stem cells (ESC) in the inner cell mass (ICM) of the 
blastocyst will develop into all tissues in the body of the human 
infant. These ICM cells are the type of cells used in ESC research. 
Normally ICM cells would become the epiblast, from which 
further stages of the embryo body-proper develop. 
2) The second type of cell in the blastocyst is called trophoblast. 
These cells develop into extra embryonic tissues (e.g., the placenta 
or umbilical cord of the infant). 
The Procedures 
Somatic Cell Nuclear Transfer: In SCNT the nucleus of an oocyte 
(egg cell), containing the genetic instructions or genome, is removed. A 
somatic cell (e.g. skin cell) is then obtained from an adult animal or from 
an adult human and the nucleus containing the genome of the donor 
somatic cell is transfened into the egg cell. In a minority of cases, the egg 
cell "reprograms" the genome of the somatic cell such that the combina-
tion of egg cell plus somatic cell genome becomes a totipotent zygote. 
If this is done with human cells and the zygote is implanted into a 
uterus, the zygote could develop into a fully grown human infant. In fact, 
according to Catholic Church teaching, the zygote itself is a human 
person.7 
Altered Nuclear Transfer and Oocyte Assisted Reprogramming: In 
both ANT in general and OAR in particular, the donor somatic cell's 
genome is altered before it is transfened to the egg cell. 
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In ANT-I, an earlier version of ANT proposed by William Hurlbut, 
M.D., the alteration of the genome involves knocking out (i.e. removing) 
one of the 30,000 human genes in the donor cell genome that is required 
for the early development of the zygote (CDX2). In ANT-I , the new entity 
therefore develops to, but not past, the blastocyst stage due to the removal 
of the CDX2 gene, which is required for development of the trophoblasts. 
The ANT-I procedure has received harsh criticism from several 
scientists and Richard Doerflinger, an ethicist for the National Conference 
of Catholic Bishops ,S because it appeared to be the production of a 
genetically defective human embryo, rather than of a non-embryo. As Mr. 
Doerflinger said, "A short lived embryo is still an embryo."8 As a result of 
these criticisms, the ANT-I procedure was abandoned as a proposal for 
research that could be ethically funded, and the OAR procedure was 
advanced in its place as a morally acceptable altemative. However, as we 
describe below, this ethical criticism of ANT-I applies even more 
rigorously to OAR. 
How Does OAR Differ From ANT-l? 
The OAR procedure starts from the fact that although all cells in the 
human body contain the entire genetic code for a human being, not all 
genes are expressed in each cell. For instance, in a skin cell only the genes 
responsible for the characteristics of a skin cell are tumed on. 
The specific set of genes which are turned on or off in a particular 
cell type is the function of certain proteins in the cell called transcription 
factors (TRF). Other mechanisms, such as methylation of the genetic 
material, also play a role in regulation of gene expression.9 The 
transcription factors , which specify the cell type, bind to certain genes in 
the genome and tum the given gene either on or off. 
It is at this point that the specific proposal of OAR begins . The 
proponents of OAR cite studies using a technique called 
immunocytochemistry to detect transcription factors that are thought to be 
absent in the zygote but present in the morula and in ES cells of the 
blastocyst. According to these studies, a transcription factor called 
"Nanog" is absent in the unfertilized mouse egg cell and in the 2-cell-stage 
embryo, but present in the morula and in higher amounts in 65% of rCM 
ES cells. 10,11 
On the strength of this finding, OAR proponents hypothesize that 
Nanog is a pivotal transcription factor that is present only in pluripotent 
cells and not in totipotent cells. II ,13 They stated: "Expression of these 
factors [transcription factors] therefore positively defines and distinguishes 
mere pluripotent cells from embryos."13 On this basis, they further 
hypothesize that Nanog is crucial for the development of a totipotent 
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zygote (human being) into a pluripotent cell. Furthermore, they claim they 
can use the presence or absence of N anog to distinguish the totipotent 
single cell zygote from the morula and ES cells which they call puripotent. 
Extrapolating from this hypothesis, OAR proponents propose to alter 
the donor cell genome by activating the gene producing Nanog before they 
transfer it into the enucleated egg cell (oocyte) and/or cause the egg cell to 
produce Nanog before the transfer. Scientists have discovered that the 
Nanog promoter has Oct4 and Sox2 binding sites, and that Oct4 and Sox2 
activate or "turn on" Nanog expression.20 Thus, the regulation of Nanog 
expression is not simple. In fact, both Oct4 and Sox2 transcription factors 
are present in the unfertilized oocyte long before Nanog is expressed in the 
morula stage of development. 21 ,22 This suggests that the presence of these 
transcription factors alone is not enough to activate Nanog. According to 
their hypothesis this early expression of Nanog suffices to ensure that the 
transfer of this altered donor cell genome into the enucleated egg cell will 
directly produce a pluripotent stem cell and not a totipotent zygote (i .e. 
human being), as critics of ANT-I thought that that procedure would have 
done. 
This hypothesis accordingly provides the basis for the judgment that 
a totipotent zygote is never present in OAR-produced cells and that no 
totipotent zygote precedes the formation of so-called plmipotent cells. This 
is also the ground of the ethical judgment that OAR is a morally acceptable 
procedure involving no creation/destruction of human embryos. 
The Ethical Problems 
There are, however, serious problems with this hypothesis which 
prevent the moral certainty required to determine that OAR overcomes 
the principal ethical dilemma involved in ANT-I, namely that the 
procedure produces a short lived embryo. Examples follow: 
1. The oocyte (egg cell) is a very powerful reprogramming cell itself. 
The enucleated oocyte can reprogram a skin cell genome, with all of its 
specifying factors including transcription factors and gene methylation, 
into totipotency in a matter of hours.9 We have Dolly the sheep and other 
cloned animals as proof of this fact. Therefore, the OAR proponents' claim 
that just one more transcription factor, i.e., Nanog, will prevent the oocyte 
from reprogramming the donor cell to totipotency seems doubtful. 
Proponents claim that the oocyte can be manipulated to express 
genes which would activate expression of mRNAs for transcription 
factors. 12, 14 However this is not sufficient. To change one cell type to a 
different cell type, the mRNA needs to be translated into the specific 
transcription factor protein; the transcription factor protein needs to be 
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processed and transported to the nucleus so it can attach to its target genes. 
Then the target genes need to be transcribed, translated and processed into 
a functional protein before a claim that the cell type has changed can be 
made. The fact that two transcription factors, Oct4 and Sox2, which 
activate the Nanog gene are present in the unfertilized oocyte 21 .22 but 
Nanog is reported to appear first in the morula stage,20 indicates that any 
genetic manipulations in the donor genes or in the oocyte will not be 
enough to activate expression of Nanog. This may be due to the fact that 
the oocyte cytoplasm removes all factors which would restrict the 
totipotency of the zygote. 
However, in the OAR entity there are at least two mechanisms which 
will prevent this cell type change from occulTing immediately. First, all 
specifying factors are removed rapidly from the donor cell genome by the 
oocyte cytoplasm9 to make a totipotent embryo. Secondly, the donor cell 
genome does not become active in directing protein synthesis and the 
development of the cell until day 2_3.2.3,4 For instance, Tong et al. showed 
that human cells are totipotent until at least the four cell stage when RNA 
synthesis starts .2 Therefore, the new entity will share the normal human 
developmental path until at least this time. 
Fm1her, OAR proponents must demonstrate that the protein products 
of the target genes prevent the initial development of a zygote.8 If these 
products act at a later stage of development, a short lived embryo will still 
have been produced by the procedure. 
2. Nanog keeps the cell, in which it is present, in the undifferentiated 
state. The most undifferentiated state is totipotency. It is therefore a leap to 
conclude that Nanog's presence necessarily overcomes totipotency to 
produce only pluripotency. 
The fact is that all that the data actually show is that Nanog keeps ES 
cells in an undifferentiated state. Thus, the presence of Nanog is perfectly 
compatible with the interpretation that OAR creates a zygote incapable of 
differentiating past the epiblast stage of development. Therefore, OAR, 
like ANT-I, is arguably the production of a crippled embryo incapable of 
fully developing into a human infant. 
3. The term pluripotent used to describe morula and ICM ES cells is 
ambiguous and not used with the same meaning by all scientists. For 
instance, John Shea, M.D., of Toronto, states, "All cells of the early human 
embryo are totipotent until shortly after the blastocyst stage."15 This same 
view is described in the testimony of David A. Prentice to the United States 
Senate.4 Further, if cultured ES cells are experimentally substituted for ES 
cells in the blatocyst, these cells can contlibute to any tissue including the 
germ line. "Thus these cells are totipotent."19 The only cells which so-
called pluripotent ES cells cannot form are the trophoblasts, which produce 
extraembryonic tissues, like the placenta, which are not essential parts of 
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the human body. Calling ES cells pluripotent instead of totipotent appears 
in this respect to be a distinction without a morally relevant difference. 
In fact, because Nanog is present in morula cells which develop to 
the blastocyst stage, we must conclude that it cannot prevent these cells 
from forming the entire blastocyst including the trophoblasts. Therefore, 
Nanog cannot be reasonably expected to prevent the new entity from 
forming the entire blastocyst including t:rophoblasts. Thus the new entity, 
even in the presence ofNanog, is totipotent in the stJ:ictest sense of this word. 
4. OAR proponents dispute this conclusion, stating that an experiment 
manipulating Nanog has not yet been done. 14 We disagree. 16 First, the 
critical experiment, showing that Nanog appears in mOlula cells before the 
trophoblast cells are formed, has already been done in mice. I I Secondly, 
Nanog measurement was not reported in the single cell zygote and was 
absent in 35% of mouse ES cells and a certain fraction of human ES cells. I I 
These findings raise questions about the claim that Nanog is a marker of 
pluripotency. Thirdly, experiments to determine presence or absence of 
Nanog in a human zygote would not be ethical because they would require 
destruction of the zygote. 17 
5. Perhaps the most dangerous ethical leap made by OAR proponents 
is their confidence that science, by itself, can answer the critical ethical 
question: Does the zygote exist even for a short time, during the OAR 
procedure? Proponents claim this is only a technical question and that 
experiments on mice will give us the answer. If these experiments support 
their hypothesis, they will be able to go on to similar human experiments 
because there is supposedly no moral issue left to be determined. 
However, there are limits to certainty in biology. For instance, the 
claim that Nanog is not detected in the 2-cell-stage embryo, using a 
specific biological procedure, is not the same as cettainty that it is absent in 
the single cell zygote. In fact, results measuring Nanog in the single cell 
zygote were not reported in the study OAR proponents cite to support their 
claim that Nanog is an essential pluripotency marker. I I In addition, the 
same study showed that Nanog was absent in 35% of mouse ES cells and 
in a certain fraction of human ES cells. I I Due to the limited statistical and 
methodological certainty allowed by biological science, the occurrence of 
technical errors in biological experiments, the difference between human 
and animal embryo development, the rapidity by which the cloning 
procedure produces a totipotent zygote, there is no biological experiment 
that will prove with certainty that a human zygote never exists during the 
OAR procedure. 
In testimony before the United States Senate, Dr. George Q. Daley, a 
preeminent stem cell researcher, stated: "Even if this strategy [OAR] 
works in mice, there is no guarantee it will work in humans, and 
verification would require the creation and destruction of many 
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manipulated human embryos, which might or might not have the altered 
characteristics that would make using human oocytes ethically 
acceptable."' 7 OAR experiments using human oocytes would require a 
control group for comparison to the OAR group. The control group would 
be normal human zygotes (i.e. human beings) which would be destroyed 
during the experiment. 
Therefore, one cannot ethically perform the experiments that are 
needed to provide the certainty required to answer the critical moral 
question (i.e., Does a human being ever exist during the OAR procedure?) 
As Dr. Daley put it: "1 am not sure you could ever satisfy the clitics. They 
could say 'Well you might get it to work but how often does it fail?"'17 Let 
us hope that a mistaken judgment by scientists based on the claim that 
OAR works in mice will not lead the Church to view the creation of 
crippled human embryos for research positively. 
6. Finally, there is a broader ethical problem with OAR. As with in 
vitro fertilization, the OAR procedure would take a component of human 
reproduction, the oocyte or egg cell. OAR then uses it in what is 
essentially a cloning procedure normally designed to produce an 
independent living entity, a procedure that would therefore otherwise be 
immoral if used on humans. Given the evidence presented above, it seems 
unfounded to conclude that activating or blocking the expression of a gene 
in this cloning procedure is sufficient to prevent it from being cloning or to 
alter the human nature of the entity it creates. 
We do not think a similar alteration in the genetic material used for 
in vitro fertilization would make the process of in vitro fertilization moral. 
Similarly, we do not think this alteration in cloning makes it any more 
morally acceptable. A combination of wrongs cannot make the end result 
good. Proponents argue that OAR is not cloning because they do not 
intend to create an embryo.14 However this begs the cIitical question 
because the SCNT procedure, used in OAR, is by definition cloning. 
A simple analogy may help illustrate the essential point that neither 
Altered Nuclear Transfer in general nor Oocyte Assisted Reprogramming 
in particular can truly bypass the production of a zygote, which, if human 
cells are used, is a human being at its earliest stage of development. 
Let's consider that the zygote is a complete book containing 30,000 
pages, one page for each gene in the genome. If you remove a single page 
-let's say, page 61, for the gene that directs development of the embryo's 
trophoblast cells at the blastocyst stage, as in ANT-l - would you have 
created something that is not a book (human person)? Or would you call it 
a defective book (crippled embryo)? 
Carrying this analogy one step further: If you also add a new page 
200 (that is, insert a gene which blocks differentiation of the embryo past 
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the epiblast stage, as in OAR), would you have an entirely new thing or 
would you have a defective book (crippled embryo)? 
The answer in both cases is obviously that you would have a 
defective book (crippled embryo). 
There are other problems with the OAR hypothesis having to do with 
the overarching and complex moral and ethical questions that sun-ound 
these procedures that would involve "harvesting" from women the egg 
cells that would be required for the purpose of producing the desired stem 
cells. But the arguments we have presented here should be enough to give 
pause as to the ethical validity of OAR. 
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